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Current screening trials are showing reduction in colorectal cancer incidence and mortality. However, participation rates are often
low, and blood-based tests could complement existing screening strategies. CD26 protein (sCD26) and its dipeptidyl peptidase IV
(DPP4) enzymatic activity in circulation have been proposed as biomarkers for colorectal cancer and other diseases. However,
changes in sCD26 and DPP4 levels show complex degrees of correlation, and their physiological or pathophysiological role is
unclear. The aim of this study was to analyse if anti-CD26 autoantibodies are related to sCD26 and DPP4 and to determine
their relevance in a context of colorectal cancer screening for complementing the value of sCD26 and DPP4 as biomarkers.
These biomarkers were measured in a large prospective cohort (n = 497, except the anti-CD26 antibodies, evaluated in 125
samples) that included a subgroup of individuals that were positive for the faecal immunological occult blood test (FIT) (n = 86)
and underwent a colonoscopy (n = 47). We confirmed for the first time higher DPP4 activity in men compared to women
(Student’s t test, p = 0:002), though this difference between sexes was not seen for serum sCD26 protein. These biomarkers
correlated (R = 0:246, p = 0:003) only in women. Correlations were found between anti-CD26 isotypes but not with DPP4
activity or sCD26 concentration, except for a negative correlation only in men between anti-CD26 IgA isotype and sCD26
(R = −0:232, p = 0:044), and an almost significant negative correlation between anti-CD26 IgG and sCD26 limited to FIT-
positive men. Interestingly, patients with advanced adenomas displayed the most elevated mean levels of anti-CD26 IgA, IgM,
and particularly IgG (Mann-Whitney U test, p = 0:030) in comparison with the other FIT positives without adenomas, and
these levels did not correlate with sCD26 or its DPP4 activity. Our preliminary results suggest that the combination of these
measures using sex as confounder could perhaps be used as biomarkers for colorectal disease. It also suggests that events
affecting the gut influence the levels of anti-CD26 antibodies, which show little or no effect in antigen clearance. These findings
should be confirmed in a larger cohort of individuals with colonoscopy. The physiological origin of the sex differences observed
should be further addressed.
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1. Introduction
Dipeptidyl peptidase IV (DPP4, EC 3.4.14.5, or CD26) is
expressed on the surface of both immune and nonimmune
(epithelial and endothelial) cell types, as well as a soluble
molecule (sCD26) found in biological fluids such as serum
[1, 2]. The N-terminal X-Pro cleaving activity from DPP4
regulates chemotactic responses to inflammatory chemo-
kines CCL 3–5, 11, and 22 and CXCL 2 and 9–12, including
SDF-1. In addition, it regulates other biologically active pep-
tides such as incretins (GLP-1), neuropeptides, and vasoac-
tive peptides [1–3]. CD26 may also participate in cell
signalling [4] and cell infiltration through its nonenzymatic
key roles in adhesion and invasion [1, 5, 6].
The role of sCD26 and DPP4 enzymatic activity in bio-
logical fluids such as plasma or serum is not clear. Neverthe-
less, changes in sCD26/DPP4 levels were found in many
diseases, suggesting a possible implication in their pathogen-
esis. Briefly, low levels of DPP4 activity or sCD26 were
observed in autoimmunity and immunosuppressed condi-
tions including certain tumours, whereas high levels occur
in other tumours, and also in infectious, inflammatory, and
liver diseases [1]. We have contributed to the study of
sCD26 concentration as a biomarker for early diagnosis
and surveillance, mainly in lung cancer and colorectal cancer
(CRC) [3, 7–10].
Recently, we have explored DPP4 enzymatic activity and
sCD26 in serum from rheumatoid arthritis and uveal mela-
noma patients and in pleural effusions of benign and malig-
nant lung diseases [10–12], finding complex degrees of
correlation including differences between sexes. Several pos-
sible arguments could explain the complex relationship
between both measures. For example, a low-molecular-
weight inhibitor of DPP4 activity was found in sera from
patients with metastatic prostate cancer [13], perhaps related
to glypican-3, recently reported as a natural inhibitor of
CD26/DPP4 enzymatic activity [14], usually absent in adult
tissues though expressed in many tumours. Likewise, the var-
iable correlations might be explained by the presence of
serum autoantibodies against CD26 [15] we have recently
studied [16] and the possibility of Ag-Ab complexes that
affect both measures.
As many studies have shown that serum autoantibodies
against tumour-associated antigens (TAAs) could serve as
potential biomarkers in the detection of several types of can-
cer [17], the aim of this study was to analyse the relationship
between DPP4 activity, sCD26 concentration, anti-CD26 iso-
types, and demographic variables, using a prospective cohort
of 497 individuals. Among these, the faecal immunological
occult blood test (FIT), currently used for CRC screening,
was offered to a subgroup of subjects. Based on the colonos-
copy result of FIT-positive individuals, we performed a
detailed analysis to explore possible improvements in the
already known value of sCD26 as a biomarker for CRC.
2. Material and Methods
2.1. Study Design. This prospective study included a total of
497 subjects: 50 healthy independent donors from the Gali-
cian Transfusion Centre (CTG, Xunta de Galicia) and 447
individuals that attended the Servizo de Vixianza da Saúde
(University of Santiago de Compostela, USC, Health Care
Unit, HCU) to perform an annual check-up. FIT was offered
to individuals aged 40-70 years from the HCU group.
Individuals were divided into the following groups: (a) 50
donors from the CTG, used to check demographic bias in the
HCU group; (b) 223 individuals from the HCU with no FIT;
(c) 138 individuals from the HCU with a negative FIT; and
(d) 86 individuals from the HCU with a positive FIT, used
to check the variables under study in the screening context.
Sex and age information of the cohort is provided in Table 1.
2.2. Ethic Statement. All the procedures described were per-
formed according to clinical ethical practices of the Spanish
and European Administrations and approved by the Local
Ethics Committee (Comité Ético de Investigación Clínica de
Galicia, Xunta de Galicia, code 2010/298). Written informed
consent was obtained from all participants, and anonymity
was warranted.
2.3. Biological Samples, FIT, and Colonoscopy. For serum col-
lection, peripheral venous blood was extracted with BD SST™
II Advance tubes, allowed to clot at room temperature, and
centrifuged at 2,000 g for 15min. Serum was stored at
-80°C until use.
The faecal occult blood (ng haemoglobin/mL) was mea-
sured using the qualitative immunological test Hem-Check
(Menarini Diagnósticos, Spain), with a detection range
between 0.04 and 120mgHb/g faeces. Stool samples were col-
lected according to the manufacturer’s instructions without
specific diet or medication restrictions.
Colonoscopy was offered only to individuals that were
positive for FIT. According to colonoscopy results, individ-
uals were classified as no colorectal findings (NCF), benign
pathology (BP; including haemorrhoids and diverticula),
hyperplastic polyps (HP), adenomas (AD) which include
tubular adenomas (TA) and tubulovillous/villous adenomas
(TV/V), and CRC.
2.4. Measurement of DPP4 Enzyme Activity and Soluble
CD26 Protein. DPP4 enzymatic activity was measured in
96-well culture plates using the substrate Gly-Pro-p-nitroani-
lide (0.2mM; Sigma-Aldrich, USA), as described previously
[10, 12]. The sCD26 concentration wasmeasured in duplicate
with the Human DPP4/CD26 DuoSet ELISA kit (R&D Sys-
tems, USA) according to the manufacturer’s instructions.
2.5. Enzyme-Linked Immunosorbent Assays for Anti-CD26
Autoantibodies. We developed an in-house ELISA for the
anti-CD26 isotypes IgG, IgM, and IgA [16]. Briefly, concen-
tration of both total and anti-CD26/DPP4 IgA, IgG, and
IgM titres in sera of the subjects was determined by ELISA
using 96-well cultured plates coated with recombinant
sCD26 (rDPP4, 0.5μg/mL) (R&D Systems, USA) prepared
in PBS pH 7.4 and blocked overnight with PBS 0.5% BSA.
Plates were incubated with different dilutions of serum for
1 h at 37°C and then washed four times with PBS 0.05%
Tween20. Goat anti-human IgM (μ-chain), anti IgG (Fab-
specific), and IgA (α-specific)-peroxidase conjugates (all
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from Sigma-Aldrich, USA) were used to detect captured anti-
bodies together with standard OPD (o-phenylenediamine
dihydrochloride) substrate (Sigma-Aldrich, USA) following
the manufacturer’s instructions. Absorbance at 450 nm was
registered using a Bio-Rad Plate reader (Bio-Rad, USA). Data
are shown as absorbance units (Abs). Specificity of the test
has been studied before [16].
2.6. Statistical Analysis. Descriptive statistics were obtained
for continuous (mean and SD) and categorical variables
(frequencies). Differences in serum DPP4 activity, sCD26
protein concentration, anti-CD26 IgG, anti-CD26 IgA, and
anti-CD26 IgM between two groups were assessed using the
parametric Student’s t test or the nonparametric Mann-
Whitney U test. The ANOVA test was carried out to com-
pare the variables among more than two groups. Pearson
correlation was used to evaluate the strength of the linear
relationship between the measured variables. Statistical anal-
yses were carried out with the software SPSS version 20
(SPSS, Chicago IL, USA).
3. Results
3.1. Levels of SerumDPP4 Activity, sCD26 Concentration, and
Anti-CD26 Autoantibody Isotypes according to Demographic
Characteristics of the Cohort. Mean and SD levels of the var-
iables measured according to sex and age are shown in
Table 2. Men exhibited higher DPP4 activity than women
(Student’s t test, p = 0:002), a difference not seen with the
concentration of the serum protein (sCD26), in coherence
with our previous works [3, 18, 19]. Anti-CD26 Ig isotypes
were measured in less samples, finding similar values in
both sexes.
In relation to age, no statistically significant differences
were found for the measurements among the three age
groups (≤50, 51-60, and ≥61 years old). Elder individuals
showed a tendency of reduced DPP4 activity and elevated
levels of anti-CD26 IgA.
3.2. Levels of SerumDPP4 Activity, sCD26 Concentration, and
Anti-CD26 Autoantibody Isotypes in the Groups of Donors
Defined according to Screening. The tendencies and differ-
ences observed in the complete cohort according to sex and
age were mainly maintained in both the CTG group and
the HCU group (Table 2). Only anti-CD26 IgM levels were
significantly lower in the HCU group in relation to the CTG
group (Student’s t test, p = 0:005). To elucidate this finding,
although the HCU and CTG groups matched age, and men
and women showed similar mean values in both groups,
IgM levels were analysed separately in the CTG and HCU
groups according to sex and age, and we found lower IgM
levels in elders (≥61 years) compared to youngers (ANOVA,
p = 0:084 for HCU and p = 0:027 for CTG).
In relation to FIT, no statistically significant differences
were found between FIT negatives and FIT positives for
any of the measures (Table 2). Likewise, the analyses accord-
ing to age indicated that both FIT-positive and FIT-negative
groups exhibited the same overall tendencies. In contrast to
the whole cohort, DPP4 activity was not different between
sexes in the FIT-positive and FIT-negative subgroups.
3.3. Levels of SerumDPP4 Activity, sCD26 Concentration, and
Anti-CD26 Autoantibody Isotypes in the FIT-Positive Group
according to the Colonoscopy Findings. Colonoscopy was
offered only to individuals with a positive FIT derived from
the HCU group, and results of colonoscopy were recorded
from 47 subjects. Individuals were classified according to
colonoscopy findings as follows: NCF, n = 8; BP, n = 12;
HP, n = 6; AD, n = 20; and CRC, n = 1. All adenomas dis-
played low-grade dysplasia. The patient with cancer had a
tumour in the rectum.
Mean and SD levels of the variables measured according
to colonoscopy findings are shown in Table 3. No statistically
significant differences were found when we compared each
pathological group with NCF and BP, considered as controls
or, conservatively, grouping NCF+BP+HP on the one hand
and AD+CRC on the other. In both cases, the adenoma
group showed the highest levels of DPP4 activity and anti-
CD26 isotypes.
To note, the NCF+BP+HP control group showed
reduced levels in comparison with the healthy donors of
Table 2, in particular IgA and IgM. The Mann-Whitney
U test performed between these two groups confirmed sta-
tistically significant differences in IgA levels (p = 0:014)
and IgM (p = 0:002). The other variables did not show dif-
ferences between the NCF+BP+HP control group and
healthy donors.
Among the 20 adenomas studied, 6 of them had a tubu-
lovillous or villous histology. Interestingly, these lesions, con-
sidered in literature as advanced adenomas due to their
Table 1: Characteristics of the individuals included in the cohort.
CTG group (n = 50) HCU group
No FIT1 (n = 223) Negative for FIT (n = 138) Positive for FIT (n = 86)
Sex
Men 21 (42.0%) 42 (18.8%) 74 (53.6%) 53 (61.6%)
Women 29 (58.0%) 20 (9.0%) 64 (46.4%) 33 (38.4%)
Age
≤50 years 27 (54.0%) — 67 (48.6%) 34 (39.5%)
51-60 years 16 (32.0%) — 50 (36.2%) 29 (33.7%)
≥61 years 7 (14.0%) — 21 (15.2%) 23 (26.7%)


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































increased risk of transforming into cancer, displayed the
most elevated mean levels of anti-CD26 IgA (0:32 ± 0:12
Abs), IgG (0:33 ± 0:06 Abs), and IgM (0:23 ± 0:13 Abs)
(NCF+BP+HP vs. AA, Mann-Whitney U test p = 0:098,
p = 0:030, and p = 0:143, respectively).
Statistical analyses were not performed separating men
from women due to the small number of individuals in each
group. However, we represented all data according to the
colonoscopy findings in men and women (Figure 1), and
the highest levels of anti-CD26 isotypes were found in some
men with tubulovillous or villous histology.
3.4. Correlations of Anti-CD26/DPP4 Autoantibody Isotype
Levels, Serum DPP4 Activity, and sCD26 Concentrations.
Correlations among these variables were first assessed in
the whole cohort (Table 4) and then separately in women
(Supplementary Table 1), in men (Supplementary Table 2),
and in the three age groups (Supplementary Tables 3-5),
due to the previous results. In the whole cohort, the
correlation found between DPP4 and sCD26 was positive
though weak (R = 0:138, p = 0:003, Figure 2(a) upper row).
Anti-CD26 isotypes significantly correlated among them,
but only IgA showed a trend to negative correlation with
sCD26 levels (R = −0:149, p = 0:084).
In men, while the correlations among isotypes remained,
sCD26 and DPP4 did not correlate (Supplementary Table 2,
Figure 2(b) upper row). However, the negative correlation
of anti-CD26 IgA vs. sCD26 was evident (R = −0:232, p =
0:044). In women, the correlation between DPP4 and
sCD26 was slightly higher (R = 0:246, p = 0:003, Figure 2(c)
upper row), and most correlations among isotypes persisted
(Supplementary Table 1).
When correlations were analysed individually in each age
group, the positive correlation between DPP4 and sCD26










































































































































































































































































































Figure 1: Levels of DPP4 activity, sCD26 protein, and anti-CD26 IgA, IgG, and IgM according to the colonoscopy findings in men and
women. Legend: NCF: no colorectal findings; BP: benign pathology; HP: hyperplasic polyp; TA: tubular adenomas; TV/V:
tubulovillous/villous adenomas; CRC: colorectal cancer. Black line represents the mean measurement in the entire cohort; red dashed lines
represent the standard deviation.
Table 4: Correlation of DPP-IV, sCD26, IgA, IgG, and IgM in all
the cohort.
DPP4 sCD26 IgA IgG IgM
DPP4 R 1 0.138∗∗ 0.038 -0.015 0.003
p value 0.003 0.661 0.867 0.968
N 484 480 134 135 135
sCD26 R 1 -0.149 -0.117 -0.021
p value 0.084 0.174 0.803
N 493 136 137 137
IgA R 1 0.441∗∗ 0.268∗∗
p value <0.0001 0.002
N 136 136 136






R: Pearson correlation coefficient.
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but was absent among the elder individuals (≥61 years)
(Supplementary Tables 3-5). These analyses also revealed a
new correlation between DPP4 activity vs. anti-CD26 IgG
that largely changed according to age; no correlation was
found in the age group ≤ 50 years, a negative correlation
appeared in the 51-60 years group (R = −0:347, p = 0:028),
and then a positive correlation was evidenced in ≥61 years
individuals (R = 0:386, p = 0:038).
In addition, correlation analyses were also performed
separately in FIT-positive and FIT-negative groups and in
the 47 individuals with a colorectal diagnosis. The DPP4
vs. sCD26 correlation was lost in FIT positives and the
subgroups with pathological colonoscopy findings (data
not shown). FIT positives showed an almost significant
negative correlation between anti-CD26 IgG and sCD26
(R = −0:220, p = 0:054, Figure 2(d) lower row), a trend lim-
ited to the ≤50 age group. Interestingly, in the nonadenoma
group that included NCF, BP, and HP, IgG correlated nega-
tively with its antigen sCD26 (R = −0:348, p = 0:019,
Figure 2(e) lower row) and almost correlated with DPP4
activity (R = −0:284, p = 0:062). However, the adenoma and
CRC groups, while maintaining the positive correlations
between the three isotypes, lacked correlation between any
anti-CD26 and sCD26 or its DPP4 activity (Figure 2(f)
lower row).
3.5. Study of the Diagnostic Possibilities of DPP4 Activity,
sCD26 Concentration, and Anti-CD26 Autoantibody Isotypes
in Men and Women. We have reported that the combina-
tion of serum sCD26 and the faecal blood test could result
a valuable strategy for detecting advanced neoplasia in
CRC screening [8].
The facts that the advanced adenomas showed the high-
est levels of the anti-CD26 isotypes and that their values do
not correlate in this group with the other biomarkers might
support the combined use of all these biomarkers for early
diagnosis of malignancy if they enhanced the number of pos-
itively diagnosed for that condition.
Figure 1 shows the values of DPP4, sCD26, and anti-
CD26 IgA, IgG, and IgM according to the colonoscopy find-
ings and also contains cut-offs to define biomarker positivity.
In this prospective study, the cut-offs were set according to
the mean ± SD of the whole cohort, based solely on the pop-
ulation distribution due to the small sample size. The outliers
or cases with levels above or below the mean + SD or −SD,
respectively, were considered positives. These cut-offs for
each biomarker are represented with dashed red lines in
Figure 1. According to this simple analysis, a larger number
of adenoma and CRC cases resulted below or above the pro-
posed cut-offs for anti-CD26 isotypes compared to sCD26.
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Figure 2: Correlation scatterplots with linear regression line. In the upper row, sCD26 vs. DPP4 in (a) the entire cohort, (b) men, and (c)
women. In the lower row, sCD26 vs. IgG in (d) FIT positives, (e) individuals with no neoplasia (no colorectal finding+benign pathology
+hyperplastic polyps), and (f) individuals with neoplasia (adenomas+cancer).
7Disease Markers
may perform better than sCD26 for detecting advanced
neoplasia.
4. Discussion
The first important result in this study was that men showed
statistically higher serum DPP4 activity than women, con-
firming the trend suggested in an early study [18]. This differ-
ence between sexes was not seen with the concentration of
the serum protein (sCD26), in coherence with what others
and we have reported several times [10–12, 19]. On the other
hand, DPP4 activity and sCD26 correlated in females but not
in males, so there is obviously an unknown factor affecting
this protein related to sex.
Serum and plasma DPP4 activity in healthy men was
slightly higher than that in healthy women at any point of
the menstrual cycle in a study that did not find significant
association between plasma DPP4 enzymatic activity and
sex [18]. However, in that study, DPP4 activity decreased sig-
nificantly with age. Therefore, the fact that serum DPP4
activity was found statistically lower in men than women in
a cohort similarly large as ours can be explained because it
is older [20].
As plasma sCD26 concentration, measured with the
same kit we used, was higher in men than in women among
healthy controls [21] (although it was not in multiple sclero-
sis (MS) patients), the difference between plasma and serum
protein concentration in relation to sex suggests that a com-
ponent of the coagulation process in serummight be interfer-
ing with the epitope used in the ELISA. It should be tested
whether plasminogen [15, 22] or fibrinogen [10], which have
been found bound to the CD26 protein, is responsible for this
variation. However, the finding that DPP4 activity correlated
with sCD26 in women but not in men might suggest, alterna-
tively, that this putative product of the coagulation system or
another activator might be enhancing serum DPP4 enzy-
matic activity in the latter. In fact, the values of serum
DPP4 activity are higher than those in plasma [18].
The physiological meaning of this fact is currently
unknown, although its importance is supported because this
weak correlation found in women (more in youngers) has
been found enhanced in patients under certain immunother-
apies in autoimmune disease [11]. In addition, the use of
DPP4 inhibitor sitagliptin, alone or together with enalaprilat
during ACE (angiotensin-converting-enzyme) inhibition
[23], diminished substance P-dependent tissue plasminogen
activator release only in women.
The correlation sCD26 vs. DPP4 found in women does
not support, however, an effect of andropause/menopause
on gene expression, which has been observed for other pepti-
dases similar to DPP4 [24]. Intriguingly, although DPP4 is
not related to the renin-angiotensin system like those pepti-
dases, it affects also blood pressure through some of its phys-
iological substrates [1, 18, 25].
However, a factor related to hormonal regulation, not
directly affecting DPP4 gene expression, cannot be excluded.
For example, it was observed that circulating levels of
25(OH)-vitamin D showed a negative correlation with
DPP4 activity inMS patients, particularly in women, suggest-
ing that vitamin D may affect DPP4 activity differently in
women and men with MS [21].
Here, we checked the relationship of anti-CD26 Abs with
the other biomarkers, taking into account that antiplasmino-
gen levels, in particular the IgG isotype, were recently related
to some tumours [26]. The only hypothesis about the origin
of anti-CD26 autoantibodies in healthy controls links again
CD26/DPP4 with plasminogen as a consequence of an
abnormal immune stimulation triggered by streptokinase
(SK) released during streptococcal infections, a mechanism
that also produces antiplasminogen [15, 22]. These authors
as well as us [16] have found elevated levels of anti-CD26
Abs in some autoimmune diseases.
Apparently, as none of the anti-CD26 values correlated
with serum DPP4 activity or sCD26 concentrations in the
cohort of healthy donors, their function is not related to
antigen clearance, as was first suggested by Cuchacovich
et al. [15] but was not confirmed in another cohort [16].
However, the significant or near significant data for neg-
ative correlations between IgA and IgG and their Ag
found in men suggests that a basal effect on sCD26 levels
cannot be discarded. Intriguingly, the same trend was not
seen in women.
Because of these or other facts, a few more individuals
with colonoscopy showed more anomalous values for DPP4
than for sCD26. However, our most remarkable finding was
the large number of individuals with anomalous anti-CD26
levels, in particular with lower IgA values in both men and
women with different benign colorectal pathologies than
the whole or the healthy cohorts. On the contrary, the group
with tubulovillous/villous adenomas exhibited higher titres
of anti-CD26 (statistically significant for the IgG isotype,
the one independent of sex and age) together with high levels
of DPP4 and low levels of sCD26.
This study has several limitations. First, the measurement
of the anti-CD26 isotypes was not possible in all the samples
included in the study, losing statistical power in some group
comparisons. Second, information regarding age and sex was
not registered in some of the individuals. Third, the analyses
regarding the subcohort of FIT-positive individuals with
colonoscopy include a small number of individuals when
grouped according to pathology, especially for individuals
with tubulovillous/villous adenomas and cancer. This pre-
vents us from performing more statistical analyses and draw-
ing more solid conclusions.
If it can be demonstrated that events in the gut are affect-
ing the normal levels of these anti-CD26 Abs, the eventual
pathophysiological role associated with them must be inves-
tigated. Some TAAs are absent or expressed at very low levels
in healthy donors, and higher antibody titres are reported
when tumours expressed the respective TAA [27]. This is
not the case of CD26 in CRC, at least in earlier stages where
CRC tumours lose the abundant epithelial CD26 expression.
Importantly, autoantibodies against autologous TAA are
detected in the asymptomatic stage of cancer and can thus
serve as biomarkers for early cancer diagnosis [28]. If the
autoantibodies were already present, the changes would still
be detected earlier since it is not necessary to trigger the
whole humoural mechanism. It may be relevant that high
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antiplasminogen levels have been found in the tumours ana-
lysed (though no information was given for colorectal
tumours [26]). Anti-CD26 might then participate in autoan-
tibody signatures that would aid in the development of diag-
nostics, prognostics, and follow-up of therapeutics for cancer
patients [27, 28] and perhaps could identify subgroups of
patients for precision medicine. Autoantibodies are also a
potential therapeutic target for cancer therapy, and some of
them are already being used in immunotherapy [29, 30].
5. Conclusion
This prospective work supports further studies to unravel the
differences between antigen sCD26 and DPP4 activity
according to sex, to know how the anti-CD26 Abs are gener-
ated, if they play a pathological role and if they may help clin-
ical daily practice (like their antigen sCD26 [8, 9]).
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